Intec Pharma Granted Chinese Patent for Accordion Pill™ Carbidopa/Levodopa
Business Wire: October 31, 2016 – JERUSALEM, Israel – Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announced that the State Intellectual Property Office of the People’s Republic of China (SIPO) has granted a Chinese patent for an Accordion Pill containing certain drugs, including the combination of carbidopa and levodopa. The patent, granted under number ZL 200980120103.9, is titled “Carbidopa/Levodopa Gastroretentive Drug Delivery” and is currently scheduled to remain in force until April 2029. The patent belongs to the company’s IN-7 patent family, which already includes patents granted in the United States, Europe, and Israel.
“We continue to globally expand and strengthen our patent portfolio for our IN-7 patent family in order to build a fortress intellectual property position that will protect our Accordion Pill technology platform,” stated Zeev Weiss, chief executive officer of Intec Pharma. “This Chinese patent secures key elements of our Accordion Pill technology platform and our leading product, the Accordion Pill Carbidopa/Levodopa, in significant markets. The Accordion Pill Carbidopa/Levodopa is currently in a global phase III clinical trial in advanced Parkinson’s disease.”
Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology. The company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The company’s product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, currently in phase III, Accordion Pill Zaleplon, or AP-ZP, which is being developed for the treatment of insomnia, including sleep induction and sleep maintenance, and an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel ulcers induced by nonsteroidal anti-inflammatory drugs. In addition, an Accordion Pill for cannabinoid therapies (AP-CBD/THC) will enter phase I clinical trial in the first quarter of 2017.
